Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu’s arteritis patients

Kang, Fei; Han, Qing; Zhou, Xiang; Zheng, Zhaohui; Wang, Shengjun; Ma, Wenhui; Zhang, Kui; Quan, Zhiyong; Yang, Weidong; Wang, Jing; Zhu, Ping

doi:10.1007/s00259-020-04871-2

Cited by 32 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PETVAS values in our study were lower than reported by Grayson et al Also, Kang et al, who reported a mean PETVAS value of 9.2, found lower numerical PETVAS values [24] than National Institutes of Health (NIH) study. Different patient characteristics may be a possible explanation for these variable results.…”

Section: Discussioncontrasting

confidence: 88%

“…Kang et all compared the performance of PETVAS and SUVmax for disease activity assessment in TAK patients. They found that PETVAS, which provides a global PET activity assessment, was superior for distinguishing active disease compared to regional assessment with SUVmax [24]. In the current study, we also observed that PETVAS were significantly higher in clinically active patients.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

2021

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 88%

Section: Discussionsupporting

confidence: 77%

Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

2021

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…One or two nuclear medicine specialists interpreted the PET/CT images and documented the presence of vasculitis lesions. Two experienced rheumatologists then blindly reviewed the patients’ PET/CT scan and visually determined a semi-quantitative PET visual score on each arterial territory using a pseudo-color spectrum scale (recommended scoring protocol: 0, no FDG uptake; 1, less than liver; 2, equal to liver; 3, greater than liver) [ 17 , 24 , 25 ]. To determine the details regarding inflammatory vascular distribution in patients with LVV, 15 specific extracranial arterial territories (ascending aorta, aortic arch, descending thoracic aorta, abdominal aorta, innominate artery, right/left carotid arteries, right/left subclavian arteries, right/left axially arteries, right/left iliac arteries, and right/left femoral arteries) were evaluated.…”

Section: Methodsmentioning

confidence: 99%

HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study

et al. 2021

View full text Add to dashboard Cite

Background This study aimed to identify new characteristics of elderly onset large-vessel vasculitis (EOLVV) by focusing on human leucocyte antigen (HLA) genotype, polymyalgia rheumatica (PMR), and affected vascular lesions observed on positron emission tomography/computed tomography (PET/CT) imaging. Methods We retrospectively studied 65 consecutive Japanese patients with large-vessel vasculitis (LVV) who had extracranial vasculitis lesions and underwent PET/CT imaging. PET/CT images were assessed using the semi-quantitative PET visual score of each affected vessel, and the PET vascular activity score (PETVAS) and number of affected vessels were calculated. Subjects were subsequently grouped based on age at onset, superficial temporal artery (STA) involvement, and presence of PMR and compared each group according to HLA genotype. Unsupervised hierarchical cluster analysis was used to identify the patients with similar characteristics in terms of affected vascular lesions detected through PET/CT imaging. The clinical characteristics and PET/CT findings of the population newly identified in this study were examined. Results Twenty-seven patients with EOLVV did not meet the American College of Rheumatology 1990 criteria for giant cell arteritis (GCA) and Takayasu arteritis and were considered as unclassified EOLVV (UEOLVV). The unsupervised hierarchical cluster analysis revealed that UEOLVV with PMR and large-vessel GCA (LV-GCA) formed a cluster of LVV with GCA features (i.e., PMR and/or STA involvement) when restricted to patients who were HLA-B52-positive. Patients who were HLA-B52-positive with LVV and GCA features had similar clinical characteristics and patterns of affected vessels and presented with diffuse LVV lesions. HLA-B52-positive patients who had LVV with GCA features also presented with higher PETVAS, more affected vessels, and lower rates of biologics usage and relapse compared to HLA-B52-positive patients with TAK. Conclusions Patients who had UEOLVV with PMR had similar characteristics to patients with LV-GCA. Patients who were HLA-B52-positive and had LVV with GCA features presented with diffuse vascular lesions and may comprise a core population of Japanese patients with EOLVV. The findings of HLA-B52 positivity and diffusely affected vessels in patients with EOLVV can be considered as suspicious findings of LV-GCA.

show abstract

“…Specifically, CD tends to demonstrate a symmetric pattern in the mediastinum and hilum [9]. The performance of qualitative over quantitative metrics in inflammatory conditions has also gained some recent interest [73]. Nonetheless, a more thorough exploration of DTP is needed to assess its efficacy in differentiating between patterns of FDG uptake and clearance in active (acute) versus inactive (chronic) inflammatory lesions in CD, which could potentially help detect acute episodes of exacerbation and monitor the underlying chronic inflammatory state of CD.…”

Section: Future Perspectives: Dual Time-point (Dtp) Imaging and Globamentioning

confidence: 99%

Emerging role of 18F-FDG PET/CT in Castleman disease: a review

et al. 2021

View full text Add to dashboard Cite

Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging.Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://clinicaltrials.gov/ct2/show/NCT02817997

show abstract

Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu’s arteritis patients

Cited by 32 publications

References 39 publications

Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study

Emerging role of 18F-FDG PET/CT in Castleman disease: a review

Contact Info

Product

Resources

About